Novartis CEO Vasant Narasimhan, MD, told Bloomberg it’s the right time to examine whether Sandoz strategically fits into the company. Sandoz’s low sales were largely attributed to the reduced cold and flu season that resulted from COVID-19 safety measures, Narasimhan said.
Novartis’ review of Sandoz, one of the largest generic drugmakers in the world, follows the move it made in 2019 to spin off Alcon, its eye care unit.
The drugmaker is seeking to deepen its focus on new treatments for cancer and other diseases, according to the report.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
